Evidence map›Paper›PMID 37071371›Full record

ArticleClinical journal of gastroenterology2023

Polymyalgia rheumatica during combination therapy with atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

Naoki Dosoden, Teiji Kuzuya, Yumi Ito, Jo Nishino, Eizaburo Ohno, Naoto Kawabe, Senju Hashimoto, Yoshiki Hirooka, Hidekata Yasuoka

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Systemic therapies in hepatocellular carcinoma: A revolution?United European gastroenterology journal · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Naoki DosodenDivision of Rheumatology, Department of Internal Medicine, Fujita Health University, Toyoake, Japan.
Teiji KuzuyaDepartment of Gastroenterology and Hepatology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan. teiji.kuzuya@fujita-hu.ac.jp.ORCID http://orcid.org/0000-0002-2229-990X
Yumi ItoDivision of Rheumatology, Department of Internal Medicine, Fujita Health University, Toyoake, Japan.
Jo NishinoDivision of Rheumatology, Department of Internal Medicine, Fujita Health University, Toyoake, Japan.
Eizaburo OhnoDepartment of Gastroenterology and Hepatology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Naoto KawabeDepartment of Gastroenterology and Hepatology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Senju HashimotoDepartment of Gastroenterology and Hepatology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Yoshiki HirookaDepartment of Gastroenterology and Hepatology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Hidekata YasuokaDivision of Rheumatology, Department of Internal Medicine, Fujita Health University, Toyoake, Japan.
Fujita Health University Hospital · JPFujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combination therapy of atezolizumab, an anti-programmed cell death ligand-1 antibody, plus bevacizumab (Atz/Bev) is widely used to treat patients with advanced hepatocellular carcinoma (HCC). The development of polymyalgia rheumatica (PMR) during immune checkpoint inhibitor therapy for patients with HCC has not been reported to date. Two patients who developed PMR during Atz/Bev therapy for advanced HCC are reported. Both patients developed fever, bilateral symmetrical shoulder pain, morning stiffness, and an elevated C-reactive protein level. Their symptoms improved rapidly with prednisolone (PSL) 15-20 mg/d, and their C-reactive protein levels decreased. In PMR, long-term low-dose PSL should be administered. In the present patients who developed PMR as immune-related adverse events, starting with a small dose of PSL resulted in rapid improvement of symptoms.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsPolymyalgia RheumaticaAntibodies, Monoclonal, HumanizedBevacizumabC-Reactive ProteinHumansPrednisoloneAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabC-Reactive ProteinPrednisoloneAtezolizumabHepatocellular carcinomaImmune-related adverse eventsPolymyalgia rheumatica

Identifiers

PMID37071371
OpenAlexW4366238171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.